이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

고에너지 정형외과 외상에 따른 통증 관리 및 장기적 결과 개선(통증 연구) (PAIN)

2026년 11월 9일 업데이트: Major Extremity Trauma Research Consortium

The purpose of this study is to definitively resolve questions regarding the use of multimodal pharmacologic pain management for orthopedic trauma patients in the context of a multicenter, randomized clinical trial.

Also, as a significant proportion of this population develops chronic post traumatic osteoarthritis (PTOA), a sub-objective of this study is to examine the etiology and incidence of chronic pain and PTOA in this population.

연구 개요

상세 설명

In this study, will test whether adjunctive analgesic therapy during the pre and peri-operative period, in addition to standard of care pain management, can improve overall pain control and pain related outcomes without increasing analgesic related side effects.

Patients will be randomized into three treatment groups. The intervention will begin within 48 hours of admission and continue for up to the time of definitive fixation.

Group 1: standard pain management, plus intravenous and oral placebo for up to 48 hours following definitive fixation.

Group 2: standard pain management, plus intravenous NSAIDs (ketorolac) and oral placebo for up to 48 hours following definitive fixation.

Group 3: standard pain management, plus intravenous placebo and oral pregabalin for up to 48 hours following definitive fixation.

Specific Aim 1: Evaluate the effect of standard pain management (Group 1) vs. standard pain management plus peri-operative NSAIDs (Group 2 - meloxicam + ketorolac) in the treatment of severe limb fractures.

Hypothesis 1a: When compared to patients who received standard of care pain management, patients treated with NSAIDs will: (1) have reduced post operative opioid utilization; (2) report reduced levels of persistent pain; and (3) have noninferior rates of surgery for nonunion.

Hypothesis 1b: When compared to patients who received standard of care pain management, patients treated with NSAIDs will benefit from (1) improved post operative pain control; (2) improved pre operative pain control; (3) reduced lengths of stay; (4) reduced pain interference; (5) improved functional outcomes; (6) lower levels of depression and post-traumatic stress disorder (PTSD); (7) improved overall health status; and (8) have noninferior rates of analgesic treatment related side effects.

Specific Aim 2: Evaluate the effect of standard pain management (Group 1) vs. standard pain management plus pre and peri-operative pregabalin (Group 3) in the treatment of severe limb fractures.

Hypothesis2a : When compared to patients who received standard of care pain management, patients treated with pregabalin will: (1) have reduced post operative opioid utilization; (2) report reduced levels of persistent pain; and (3) have noninferior rates of surgery for nonunion.

Hypothesis 2b: When compared to patients who received standard of care pain management, patients treated with pregabalin will benefit from (1) improved post operative pain control; (2) improved pre operative pain control; (3) reduced lengths of stay; (4) reduced pain interference; (5) improved functional outcomes; (6) lower levels of depression and post-traumatic stress disorder (PTSD); (7) improved overall health status; and (8) have noninferior rates of analgesic treatment related side effects.

Specific Aim 3: Estimate the incremental cost effectiveness of each adjunctive analgesic therapy relative to standard of care analgesic therapy in the treatment of severe limb fractures. Costs will be estimated from both the health care provider perspective and the societal perspective. The time horizon for cost-effectiveness analysis will be based on the actual period of observation. Incremental cost-effectiveness ratios will be calculated for: (a) study group 2 (NSAIDS - meloxicam + ketorolac) relative to standard of care; and (b) study group 3 (pregabalin) relative to standard of care. For purpose of cost-effectiveness analysis, the effect will be measured as unit change in specific outcome metrics at up to 15 months (or longer period as available) compared to baseline. The following cost-effectiveness metrics, all relative to standard of care, will be reported:

  1. incremental cost per unit change in the Brief Pain Inventory
  2. incremental cost per unit change in the Short Muscular Function Assessment (SFMA)
  3. incremental cost per unit change in health state preference ("utility") as derived from the VR-12.

PTOA Pilot Study: Additional funding was received from NIH to conduct a pilot, observational study of post-traumatic osteoarthritis (PTOA), leveraging current resources of the Pain study. PTOA is an important outcome in the population to be enrolled in the Pain study. The aims of the PTOA Study are to: (1) measure the incidence of PTOA and chronic pain for up to 24 months following fracture reduction surgery and (2) quantify the extent to which fracture severity and post-reduction contact stress are related to the development of PTOA. Accomplishment of these aims will require (1) for all patients with ankle fractures in the Pain study: complete a PTOA survey at 12 months and at any subsequent visits that are conducted as part of standard of care and provide access to all standard of care imaging studies completed during the study period and (2) for a subset of 60 pilon fracture patients enrolled in the Pain study for whom post-operative CT scans are not standard of care, obtain additional consent for completion of a study-funded post-operative CT scan and 24 month radiographic study

연구 유형

중재적

등록 (실제)

450

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Florida
      • Miami, Florida, 미국
        • University of Miami Ryder Trauma Center
      • West Palm Beach, Florida, 미국
        • St. Mary's Medical Center
    • Indiana
      • Indianappolis, Indiana, 미국
        • Eskenazi Health
    • Iowa
      • Iowa City, Iowa, 미국
        • University of Iowa Hospitals & Clinics
    • Louisiana
      • Shrevport, Louisiana, 미국
        • Louisiana State University Health Sciences Center
    • Maryland
      • Baltimore, Maryland, 미국
        • Johns Hopkins University
      • Baltimore, Maryland, 미국
        • University of Maryland, R Adams Cowley Shock Trauma Center
    • Massachusetts
      • Boston, Massachusetts, 미국
        • Boston Medical Center
    • Minnesota
      • Minneapolis, Minnesota, 미국
        • Hennepin County Medical Center
    • North Carolina
      • Charlotte, North Carolina, 미국
        • Carolinas Medical Center
    • Ohio
      • Cleveland, Ohio, 미국
        • MetroHealth Medical Center
    • Pennsylvania
      • Hershey, Pennsylvania, 미국
        • Penn State University M.S. Hershey Medical Center
      • Pittsburgh, Pennsylvania, 미국
        • University of Pittsburgh
    • Tennessee
      • Nashville, Tennessee, 미국
        • Vanderbilt University Medical Center
    • Texas
      • Dallas, Texas, 미국
        • University of Texas Southwestern Medical Center
      • Houston, Texas, 미국
        • UT Health: The University of Texas Health Science Center at Houston Medical School
    • Virginia
      • Portsmouth, Virginia, 미국
        • Naval Medical Center Portsmouth

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Patients with one of the following types of injuries:

    1. Unilateral, Grade I &II open or closed pilon (distal tibial plafond), calcaneus, talus fractures and Lisfranc dislocations requiring operative treatment with fixation; or
    2. Unilateral, open (type I, II, or IIIA) ankle fractures with associated dislocation on presentation (OTA 44B3 or 44C) requiring operative treatment with fixation; or
    3. Unilateral, open or closed distal and proximal humerus (OTA 11A-C and OTA 13 A-C); or
    4. Open femoral shaft fracture (OTA 32 A-C; Gustilo Type I-IIIC) or open or closed supracondylar femur fractures (OTA 33 A-C); or
    5. Open or closed tibial plateau or shaft fractures (OTA 42 A-C or 43 A-C)
    6. Any combination of the above injuries which are surgically treated as a whole
  2. Patients who present to the admitting hospital acutely or clinic following an initial assessment in the Emergency Department, for care up to 10 days following initial injury.

  3. Patients 18-80 years old inclusive.

  4. Patients who are English or Spanish competent.

  5. Treating physicians agree that none of the study drugs are indicated for standard of care treatment for this patient.

  6. Patients able to be followed at the METRC facility for at least 12 months following injury.

Exclusion Criteria:

  1. Patients unable to provide informed consent.
  2. Patients with chronic pain being presently treated with opioid or gabapentinoid prescription or any other alternative therapy.
  3. Patients who are current IVDA
  4. Patients with bilateral or ipsilateral injuries requiring surgery
  5. Patients with other orthopedic or non-orthopedic injuries requiring operative intervention
  6. Patients with severe osteopenia.
  7. Patients who are skeletally immature (defined as less than 18 years of age or no radiographic evidence of epiphyseal closure).
  8. Patients who are expected to have a post-surgical stay less than 24 hours.
  9. Patients with a history of allergy to any drugs in the study.
  10. Patients unable to swallow oral medications or without adequately functioning GI tract.
  11. Patients with a history of gastrointestinal bleeds or gastric perforation.
  12. Patients with a history of stroke or heart attack.
  13. Patients currently receiving an aspirin or NSAID regimen (exception: low dose (81 mg) aspirin. See section 6.5) Patients with any bleeding disorders.
  14. Patients with severe renal failure. Patients with moderate renal failure may participate in the study at a modified dose. See Section 9.6.
  15. Patients undergoing daily treatment with systemic glucocorticoids before surgery.
  16. Patients using angiotensin-converting enzyme (ACE) inhibitors, who may be at increased risk of developing angioedema with pregabalin.
  17. Patients likely to have severe problems maintaining follow-up, including patients diagnosed with a severe psychiatric conditions, patients who live too far outside the hospital's catchment area, patients who are incarcerated and patients who have unstable housing situations.
  18. Patients who experienced a loss of consciousness consistent with a clinical diagnosis of a closed head injury, or concern of a cerebrovascular bleed secondary to traumatic brain injury.
  19. Patients with a GCS <15
  20. Patient speaks neither English nor Spanish.
  21. Patients who are pregnant or lactating at time of screening

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: Placebo

Standard pain management + perioperative intravenous placebo & oral placebo.

Control group will receive an oral dose of placebo up to two hours prior to surgery and twice daily for up to 48 hours following any surgery, in addition to an intravenous dose of placebo up to two hours prior to surgery and every 6 hours for up to 48 hours following surgery. All study medications will be in addition to standard of care pain medication.

*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall.

활성 비교기: NSAID

Standard pain management + perioperative intravenous ketorolac & oral placebo.

The NSAID group will receive 30 mg of intravenous (IV) ketorolac (Ketorolac 30 mg/ml dose vial, NDC 00409-3795-01; manufacturer: Hospira) administered up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an oral dose of placebo up to two hours prior to the procedure and every 12 hours for up to 48 hours following the procedure.

*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall.

다른 이름들:
  • Meloxicam/Mobic(NDC 68382-000-01, 제조업체: Zydus, AA 크기로 캡슐화됨)
  • Fisher Clinical Services(Bristol)의 Avicel로 다시 채워진 빈 캡슐 껍질
  • LLC)
  • 케토로락/토라돌(NDC 00409-3795-01; 제조업체: Hospira)
활성 비교기: Gabapentinoid

Standard pain management + perioperative intravenous placebo & oral pregabalin.

The Pregabalin group will receive an oral bolus dose of 300 mg of pregabalin up to two hours prior to the procedure and a 75 mg dose every 12 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an IV dose of placebo up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure.

*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall.

다른 이름들:
  • Pregablin/Lyrica(NDC 00071-1014-68, 제조업체: Pfizer, 캡슐화된 크기
  • Fisher Clinical Services에서 Avicel로 다시 채운 AA 빈 캡슐 쉘
  • (브리스톨) LLC,; Lyrica, NDC 00071-1018-68; 제조업체: 화이자; 캡슐화
  • Fisher Clinical의 Avicel로 다시 채워진 AA 크기의 빈 캡슐 쉘
  • 서비스(브리스톨) LLC)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Opioid Utilization
기간: 48 hours after last definitive fixation

Morphine equivalent opioid utilization during initial hospitalization through 48 hours following definitive fixation.

48 hours after last definitive fixation
Persistent Pain
기간: 90 days

Patient reported persistent pain states measured using the Brief Pain Inventory (BPI) .

90 days
Surgery for non-union
기간: 1 year

Defined as non-prophylactic surgery for nonunion performed between six months and a year following initial hospital discharge.

1 year

2차 결과 측정

결과 측정
측정값 설명
기간
Adverse Effects and Complications
기간: 2-3 weeks

Will include nonunion, wound closure complications, bleeding complications (particularly perioperative bleeding due to loss of platelet function and gastrointestinal bleeding), as well as pain treatment related adverse effects. These include nausea, vomiting, constipation, sedation, pruritis, respiratory depression, somnolence, dizziness, headaches, coordination problems, peripheral edema, blurred vision, gastrointestinal symptoms and irritation, renal impairment, platelet inhibition, angioedema, and post operative delirium. Adverse effects and complications will be assessed by both patient report of symptoms during the period between enrollment and 48 hours post definitive fixation, and by clinical survey of symptoms during index hospitalization and at discharge from additional surgical admissions up to definitive fixation.

2-3 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Lawrence Marsh, MD, University of Iowa Hospitals & Clinics
  • 연구 책임자: Katherine Frey, RN, MPH, MS, Johns Hopkins Bloomberg School of Public Health
  • 수석 연구원: Renan Castillo, PhD, Johns Hopkins Bloomberg School of Public Health

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2013년 7월 1일

기본 완료 (실제)

2018년 12월 31일

연구 완료 (실제)

2018년 12월 31일

연구 등록 날짜

최초 제출

2013년 2월 7일

QC 기준을 충족하는 최초 제출

2013년 2월 11일

처음 게시됨 (추정된)

2013년 2월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다